Umifenovir Contributes to Clinical and Laboratory Improvement of COVID-19 Management
A randomized controlled trial was conducted to evaluate the efficacy of umifenovir as a monotherapy for the hospitalized patients with COVID-19.
Treatments
Early Data Show Regeneron Cocktail Prevents Symptomatic COVID-19 Infection
REGEN-COV consists of 2 potent, virus-neutralizing antibodies that bind noncompetitively to the receptor binding domain of the SARS-CoV-2 spike protein.
Comparing Culture-Positive and -Negative Pyogenic Vertebral Osteomyelitis
The goal of this study is to investigate the antimicrobial therapy, therapeutic response, and outcome of culture-negative PVO compared with culture-positive PVO.
WHO: Remdesivir, Hydroxychloroquine, Lopinavir, Interferon Ineffective for COVID-19
World Health Organization expert provided data on 4 repurposed antiviral drugs – remdesivir, hydroxychloroquine, lopinavir, and interferon beta-1a – and its use in patients hospitalized with COVID-19.
Regeneron’s Antibody Cocktail Reduces COVID-19 Viral Load in Phase 1/2 Trial
Regeneron’s antibody cocktail for COVID-19, REGN-COV2, contains 2 neutralizing antibodies: casirivimab and imdevimab; results from the phase 1/2 trial reveal promising results for patients who were antibody-negative or had high viral loads.
Valganciclovir and Ganciclovir Effective for HIV-Associated CMVR in Low- and Middle-Income Countries
The study authors describe the first use of valganciclovir treatment in lower-income countries for patients with CMVR, advanced HIV disease, and profound immunosuppression.
Switch From Efavirenz to Integrase Strand Transfer Inhibitors Related to Weight Gain
Researchers studied 61 HIV-infected individuals who switched from efavirenz- to integrase strand transfer inhibitor (INSTI)-based therapies.
Updates and Challenges for WHO Antibiotic Targets
Investigators reviewed patterns of antibiotic consumption in each of the WHO Access, Watch, and Reserve (AWaRe) categories over a span of 15 years and documented changes.
Darunavir Resistance Development Is Rare in HIV Treatment
Researchers evaluated the results of multiple phase 2 and phase 3 clinical trials and found that drug resistance to darunavir, an HIV protease inhibitor, is rare.
Prior Care Experiences Determine Antibiotic Prescribing for Future Acute Respiratory Illness
One potential driver of high antibiotic prescribing rates for acute respiratory infections is patient’s prior care experiences.
- Loading...
Loading...
Next post in Practice Management
Loading... 
Loading...